Terns Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TERN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
TERN on Nasdaq
Shares outstanding
108,024,600
Price per share
$35.48
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
58,439,899
Total reported value
$2,361,147,033
% of total 13F portfolios
0.01%
Share change
+260,402
Value change
+$36,055,372
Number of holders
146
Price from insider filings
$35.48
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Terns Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TERN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MORGAN STANLEY 8.1% $20,731,866 7,099,954 Morgan Stanley 31 Mar 2025
BlackRock, Inc. 6.8% $16,770,967 5,743,482 BlackRock, Inc. 31 Dec 2024
Commodore Capital LP 6.5% +24% $42,807,000 +$7,885,500 5,700,000 +23% Commodore Capital LP 30 Sep 2025
Adage Capital Management, L.P. 5.1% $196,914,000 5,550,000 Adage Capital Management, L.P. 31 Dec 2025
VANGUARD GROUP INC 5.2% $34,244,977 4,559,917 The Vanguard Group 30 Sep 2025
Schonfeld Strategic Advisors LLC 4.9% -20% $12,571,196 -$2,713,568 4,305,204 -18% Schonfeld Strategic Advisors LLC 31 Mar 2025
ORBIMED ADVISORS LLC 4.8% $31,842,911 4,240,068 ORBIMED ADVISORS LLC 03 Nov 2025
CITADEL ADVISORS LLC 4.1% $10,118,696 3,465,307 Kenneth Griffin 31 Dec 2024
Deep Track Capital, LP 3% -62% $111,762,000 -$154,160,600 3,150,000 -58% Deep Track Capital, LP 31 Dec 2025
Vivo Opportunity Fund Holdings, L.P. 2.5% $95,817,820 2,700,615 Vivo Opportunity Fund Holdings, L.P. 31 Jan 2025
Soleus Capital Master Fund, L.P. 0.2% -94% $7,546,951 -$281,348,949 212,710 -97% Soleus Capital Master Fund, L.P. 31 Dec 2025

As of 31 Dec 2025, 146 institutional investors reported holding 58,439,899 shares of Terns Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TERN). This represents 54% of the company’s total 108,024,600 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Terns Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TERN) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.6% 8,194,218 +48% 0.01% $331,046,406
MORGAN STANLEY 7.4% 7,945,608 +4.7% 0.02% $321,002,599
VANGUARD GROUP INC 5.1% 5,523,948 +21% 0% $223,167,499
Vivo Capital, LLC 4.9% 5,346,928 -22% 14% $216,015,891
FRANKLIN RESOURCES INC 2.5% 2,731,312 +114% 0.03% $110,345,002
LORD, ABBETT & CO. LLC 2.5% 2,712,399 0.34% $109,581,000
GEODE CAPITAL MANAGEMENT, LLC 1.9% 2,096,642 +22% 0.01% $84,723,240
STATE STREET CORP 1.6% 1,775,922 +11% 0% $71,747,249
JPMORGAN CHASE & CO 1.6% 1,773,026 +160% 0% $71,630,251
Pictet Asset Management Holding SA 1.5% 1,577,116 +43% 0.06% $63,745,572
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 1.4% 1,515,400 0.1% $61,222,160
Candriam S.C.A. 1.2% 1,262,303 -47% 0.26% $50,999,212
DIMENSIONAL FUND ADVISORS LP 1.2% 1,247,763 -14% 0.01% $50,410,160
Nuveen, LLC 1% 1,078,157 -27% 0.01% $43,557,543
GOLDMAN SACHS GROUP INC 0.98% 1,062,984 +94% 0.01% $42,944,553
Capital International Investors 0.98% 1,060,000 0.01% $42,824,000
MARSHALL WACE, LLP 0.81% 878,583 0.03% $35,494,753
First Turn Management, LLC 0.81% 872,049 4% $35,230,780
Deep Track Capital, LP 0.71% 769,048 -90% 0.71% $31,069,539
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.68% 737,160 +26% 0% $29,781,264
NEXTBio Capital Management LP 0.51% 551,190 0% 13% $22,268,076
Affinity Asset Advisors, LLC 0.51% 550,000 1.6% $22,220,000
Mariner, LLC 0.5% 542,052 0.03% $21,898,859
RENAISSANCE TECHNOLOGIES LLC 0.43% 466,847 -31% 0.03% $18,860,619
DEUTSCHE BANK AG\ 0.37% 401,446 +5.4% 0.01% $16,218,419

Institutional Holders of Terns Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TERN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 58,439,899 $2,361,147,033 +$36,055,372 $40.40 146
2025 Q3 88,633,130 $665,700,838 +$50,617,366 $7.51 140
2025 Q2 83,108,168 $309,995,477 +$2,354,788 $3.73 126
2025 Q1 83,089,113 $229,386,277 -$20,904,178 $2.76 134
2024 Q4 86,147,142 $477,240,000 +$3,828,882 $5.54 156
2024 Q3 79,491,087 $663,002,763 +$119,235,330 $8.34 153
2024 Q2 65,586,958 $446,681,549 +$17,184,836 $6.81 124
2024 Q1 63,239,404 $414,841,261 -$1,823,851 $6.56 112
2023 Q4 63,584,855 $412,672,679 +$14,024,936 $6.49 102
2023 Q3 61,708,912 $310,396,950 +$8,574,392 $5.03 92
2023 Q2 57,715,917 $505,015,397 +$31,653,493 $8.75 102
2023 Q1 53,226,532 $630,202,113 +$46,248,002 $11.84 79
2022 Q4 49,723,793 $506,193,882 +$199,453,477 $10.18 65
2022 Q3 30,203,299 $177,898,000 +$107,051,162 $5.89 43
2022 Q2 14,707,603 $36,472,000 -$6,462,439 $2.48 37
2022 Q1 16,836,162 $50,004,000 -$1,388,822 $2.97 43
2021 Q4 16,503,387 $116,663,000 -$4,531,477 $7.07 37
2021 Q3 16,724,968 $174,276,000 +$979,766 $10.42 33
2021 Q2 16,621,217 $203,777,000 -$24,794,385 $12.26 36
2021 Q1 17,905,204 $393,648,000 +$393,098,000 $22.00 41